SCHEMBL3275891

SCHEMBL3275891

Cc1ccc(C(=CCSc2ccc(OCC(=O)O)c(I)c2)c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.62
PPARA Q07869 1/20 0.46
PTGDR2 Q9Y5Y4 6/20 0.44
MAPT P10636 2/20 0.38
TBXAS1 P24557 1/20 0.38
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274693 1.00 PPARD (0.62) PPARDPPARAPTGDR2MAPTTBXAS1
SCHEMBL3271025 0.97 PPARD (0.66) PPARDPPARAPTGDR2MEN1KMT2A
SCHEMBL3270293 0.92 PPARD (0.58) PPARDPPARAPTGDR2LMNAL3MBTL1
SCHEMBL3271163 0.92 PPARD (0.58) PPARDPPARAPTGDR2LMNAL3MBTL1
SCHEMBL3270074 0.91 PPARD (0.59) PPARDPPARAPTGDR2L3MBTL1MEN1
SCHEMBL3270077 0.91 PPARD (0.59) PPARDPPARAPTGDR2L3MBTL1MEN1
SCHEMBL3270411 0.90 PPARD (0.58) PPARDPPARAPTGDR2TBXAS1LMNA
SCHEMBL3274214 0.90 PPARD (0.58) PPARDPPARAPTGDR2L3MBTL1MEN1
SCHEMBL3270701 0.90 PPARD (0.58) PPARDPPARAPTGDR2L3MBTL1MEN1
SCHEMBL3270413 0.90 PPARD (0.58) PPARDPPARAPTGDR2TBXAS1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP claimed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US claimed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US claimed
EP-1558572-B1 NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2010-06-30 EP disclosed
US-7129268-B2 Peroxisome proliferator activated receptor-active arylene acetic acid derivatives NOVO NORDISK A/S (DK) 2006-10-31 US disclosed
US-20050070583-A1 Novel compounds, their preparation and use VTVX HOLDINGS II LLC 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070583-A1 Novel compounds, their preparation and use PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885PTGDR2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.